Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rang in Aktien #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Aktienkurs
$265.95
Marktkapitalisierung
$469.88B
Veränderung (1 Tag)
0.34%
Veränderung (1 Jahr)
19.48%
Land
US
Handel AbbVie Inc. (ABBV)

Kategorie

Operative Marge für AbbVie Inc. (ABBV)
Operative Marge zum September 2026 TTM: 29.32%
Laut den neuesten Finanzberichten und dem Aktienkurs von AbbVie Inc. beträgt die aktuelle operative Marge (TTM) 29.32%. Am Ende des Jahres 2024 lag die operative Marge bei 16.22%.
Historie der operativen Marge von AbbVie Inc. von 2009 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) 29.32% -15.48%
2025 34.69% 113.87%
2024 16.22% -30.95%
2023 23.49% -24.74%
2022 31.21% -2.13%
2021 31.89% 28.54%
2020 24.81% -36.43%
2019 39.03% 100.26%
2018 19.49% -42.39%
2017 33.83% -7.14%
2016 36.43% 10.49%
2015 32.97% 92.92%
2014 17.09% -43.30%
2013 30.14% -4.77%
2012 31.65% 52.53%
2011 20.75% -31.20%
2010 30.16% -13.08%
2009 34.70% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
43.92% -98.50%
US
26.81% -99.09%
US
26.59% -99.09%
CH
16.65% -99.43%
US
31.24% -98.93%
CH
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.